Activating mutations of oncogenes such as KRAS, BRAF or PIK3CA that are common to colon cancer have been reported to be associated with resistance to cytotoxic agents or molecularly targeted drugs [46]. This evidence concerns the gene KRAS and colonic neoplasm.